SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : The Microcap Kitchen: Stocks 5ยข to $5 -- Ignore unavailable to you. Want to Upgrade?


To: GARY P GROBBEL who wrote (847)3/13/2001 12:45:50 PM
From: GARY P GROBBEL  Respond to of 120405
 
i have been in and out of nymx several times so far this year...they are on to something i believe and the nature of the illness and its prospects should keep nymx in the news...this today...2.25 on nasdaq:

(COMTEX) B: Nymox Developing New Drug Candidates for the Treatment of
B: Nymox Developing New Drug Candidates for the Treatment of Alzheimer's
Disease

MAYWOOD, N.J., Mar 13, 2001 (BW HealthWire) -- Nymox Pharmaceutical Corporation
(NASDAQ: NYMX) announced today that it is increasing its development efforts in
the areas of diagnosing and treating Alzheimer's disease, the leading cause of
dementia among the elderly.

This is National Brain Awareness Week (March 12 -18) across the United States,
Canada and Europe. Brain Awareness Week is an annual public information campaign
sponsored by the Society for Neuroscience in conjunction with the Dana Alliance
for Brain Initiatives and designed to raise public awareness of brain and
nervous system research.

Nymox has two principal development programs aimed at Alzheimer's disease, both
based on original research into the possible causes of this terminal brain
disease. The findings illustrate how basic research in neuroscience can lead to
promising new drug treatments for Alzheimer's disease and new diagnostic tools
for physicians.

The first program targets spherons, tiny dense balls of protein found in the
brains of everyone from age one. Spherons are the only normal new brain
structure visible through the light microscope found in the last century. The
fact that they are not visible by the most routine neuroscience methods may have
contributed to their surprisingly late characterization.

Nymox researchers believe that spherons are the principal source of the senile
plaques, the characteristic abnormality found in abundance in crucial areas of
the brains of patients with Alzheimer's disease and widely believed to play a
pivotal role in the cause and course of the illness. The researchers found that,
as we grow older, spherons enlarge until they can no longer be held by their
brain cells. When they reach their maximum size of 5 to 10 microns in diameter,
they burst, creating the senile plaques and setting off a cascade of cellular
damage and biochemical changes that are instrumental to the symptoms and signs
of Alzheimer's disease.

In 1998, Nymox researchers summarized their findings linking spherons to senile
plaques and Alzheimer's disease in the Journal of Alzheimer's Disease and Drug
News & Perspectives. These summaries set forth 20 important criteria of validity
correlating the disappearance of spherons in old age with the appearance of
senile plaques and implicating spherons as a significant cause of Alzheimer's
disease. In 2000, an international group of researchers from the United States,
Canada and the United Kingdom published further findings in Alzheimer Reports
(2000; 3: 177-184) confirming that spherons contain key proteins that are also
known to be in senile plaques and showing that, like senile plaques, spherons
contain unusually old proteins in terms of the human body's metabolism, with an
average age of 20 to 40 years.

Nymox researchers believe that stopping or inhibiting the transformation of
spherons into senile plaques will stop or slow the progress of this devastating
disease. They extracted spherons from human brain tissue and developed novel,
proprietary drug screening methodologies and promising new drug candidates based
on spherons.

Nymox's second Alzheimer's disease drug development program targets a brain
protein called neural thread protein (NTP) which is elevated early in
Alzheimer's disease as reported both in the scientific literature and at
scientific conferences. Researchers at the Massachusetts General Hospital and
Brown University led by Doctors Suzanne de la Monte and Jack Wands first found
large amounts of the protein in the brains of patients known to have died with
Alzheimer's disease. Subsequent research at Harvard and Brown led to the
characterization of NTP and the gene that produces it. Nymox succeeded in
developing a highly sensitive test to detect the presence of NTP in the spinal
fluid and, most recently, in the urine of patients with Alzheimer's disease.

To date, many independent studies published in peer-reviewed scientific
publications or presented at scientific conferences have confirmed the accuracy
of NTP as a marker for Alzheimer's disease. These publications include, for
example, the Journal of Neuropathology and Experimental Neurology (1996; vol.
55: 1038-1050), Journal of Clinical Investigation (1997; vol.100; pages
3093-3104), Journal of Contemporary Neurology (1998; art. 4a), Journal of
Clinical Laboratory Analysis (1998; vol.12: 223-226) and (1998; vol.12:
285-288), Alzheimer's Reports (1999; vol.2: 327-332) and (2000; vol.3: 177-184),
and Neurology (2000; vol. 54: 1498-1504).

Nymox is currently marketing a clinical reference laboratory test, known as
AlzheimAlert(TM), that detects elevated levels of NTP in the urine of patients
with Alzheimer's disease. The results of this unique and accurate urine test can
assist a physician faced with the task of diagnosing whether a patient has
Alzheimer's disease. Nymox offers the test at a cost of $295 through its
reference laboratory in Maywood, New Jersey.

Based on the research that led to the discovery of NTP and evidence linking NTP
to the cell loss found in Alzheimer's disease, Nymox has also developed a unique
drug screening system to identify other potential drug candidates for the
treatment of Alzheimer's disease. These potential drug candidates are aimed to
reduce or prevent the cell loss associated with high levels of NTP. Recently,
Dr. Suzanne de la Monte and Dr. Jack Wands of Brown University published the
results of a series of experiments in the February, 2001, issue of the Journal
of Neuropathology and Experimental Neurology (Vol. 60, No.2, pp. 195-207), a
prestigious peer-reviewed medical journal, which provided further evidence of
the key role played by NTP in Alzheimer's disease. The researchers implanted the
gene that produces NTP in nerve cells derived from humans. They then induced the
cells to turn on the NTP gene and to begin producing NTP in elevated quantities.
This caused a marked increase in nerve cell death. Sophisticated analysis showed
that the cells died in a programmed fashion similar to the way the nerve cells
in brains of patients with Alzheimer's disease die. Extensive loss of brain
cells and accompanying brain shrinkage is a key part of the Alzheimer's disease
process.

Nymox Pharmaceutical Corporation has facilities in Montreal and Maywood, NJ. Its
stock is traded on NASDAQ with the symbol NYMX. More information is available at
nymox.com.

This press release contains certain "forward-looking statements" as defined in
the United States Private Securities Litigation Reform Act of 1995 that involve
a number of risks and uncertainties. There can be no assurance that such
statements will prove to be accurate and the actual results and future events
could differ materially from management's current expectations. Such factors are
detailed from time to time in Nymox's filings with the United States Securities
and Exchange Commission and other regulatory authorities.


CONTACT: Nymox Pharmaceutical Corporation
Dr. Michael Munzar, 1-800-93NYMOX
www.nymox.com
or
Sitrick & Company
Lew Phelps, 310/788-2850

URL: businesswire.com
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.

Copyright (C) 2001 Business Wire. All rights reserved.

-0-


KEYWORD: NEW JERSEY
INDUSTRY KEYWORD: MEDICAL
PHARMACEUTICAL

*** end of story ***



To: GARY P GROBBEL who wrote (847)3/16/2001 7:48:21 PM
From: sheetmillgalvanize  Respond to of 120405
 
cnbc.com

other Kudlow topics.........

cnbc.com

Kudlow: S&P 1560?
By Lawrence Kudlow
Contributing Editor

Mar 7, 2001 03:56 PM

So far it hasn't been much of a new millenium for stocks, which have been hit hard by shrinking profits, a slumping economy, tight money, energy shocks, rising tax burdens and dot.com deflation. Market pessimism and cynicism are out in full force. Bulls have mostly stayed behind closed doors.

But there's an obvious bright spot in the outlook that is too often overlooked: declining interest rates. Across the maturity spectrum, Treasuries, investment-grade corporates, high yield corporates, and tax-exempts have been declining in yield.

For the economy and the stock markets, this means that help is on the way. In particular, the decline of short-term interest rates, which began in November for Treasury bills, and January for commercial paper and the bank prime rate, bodes well for recovery.

Especially the signal from three-month Treasury bills, a frequently ignored rate that captures short-term variations in the economy, inflation expectations and inflation-driven tax burdens (such as the unindexed capital gains tax).

Also, of course, the T-bill rate captures expected and actual Federal Reserve policy moves. Last November the declining bill rate correctly anticipated the January Fed U-turn toward less restrictive money. Now the drop in T-bill rates is signaling a declining inflation tax on the economy and an increase in financial liquidity. These are good things.

The Treasury bill rate also has significant forecasting properties. In models developed years ago by economists Arthur Laffer and Victor Canto, and various offshoot models used by many others (including myself), the T-bill rate sends two messages.


First, as a coincident indicator, the bill rate tracks the current economy. For example, the steep bill decline, from 6.44% last November to 4.70 percent recently, marks the unexpected collapse of economic growth from a robust 5.3 percent in last year's first half to a discouraging 1.7 percent in the second half.

Second, as a forecasting indicator, with variable lags of six to twelve months (or sometimes longer), the bill rate predicts future economic growth and profits. Assuming the T-bill rate falls to 4.25 percent this year, our version of the model suggests 1.1 percent annualized real GDP growth for first-half 2001 and 2.8 percent in the second half.

In terms of profits, the T-bill model predicts that the four-quarter change in after-tax S&P 500 operating earnings comes in at a negative 2.6 percent in Q1, then 0.9 percent in Q2, 4.7 percent in Q3 and 6.6 percent in Q4.

As for the stock market, the T-bill rate can be used as a discount factor to capitalize expected future earnings. Dividing expected profits by the T-bill rate provides capitalized profits, a proxy for future stock market value. With falling T-bill rates and a modest profit improvement, the model projects capitalized earnings to rise 40 percent by yearend 2001. This is a significant buy signal for the S&P stock market, which could rise by roughly 25 percent from current levels.

For skeptics, it is noteworthy that the T-bill model of capitalized earnings put out a sell signal eighteen months ago. From mid-1999 through the end of 2000, capitalized earnings declined by 17 percent (as T-bill rates rose significantly, while profits slowed). The drop in capitalized earnings foreshadowed the subsequent market slump.

Importantly, the T-bill model of capitalized profits and the stock market captures a basic investing truth. When the Fed is tightening, get out of the way. However, when the Fed is easing, get back into the game. Rising short rates often trump strong earnings. Falling short rates often override week earnings. Capitalized profits tell the story.

Right now the Fed is easing, a big plus for investors. Additionally, declining energy prices become increasingly less of a drag on corporate profits and consumer purchasing power. Also, the Y2K hangover (huge over-investment in 1999, borrowed from 2000 and 2001) may soon be coming to an end. And while technology stocks are way down, the economic benefits of the long-cycle technology innovation and spillover wave are alive and well.

Meanwhile, while the Fed may belatedly lower the funds rate another 100 basis points, the House Ways and Means tax bill will delay the supply-side effects of lower marginal tax-rates until 2002 and beyond. This will dilute the potential economic boost to investment and capital formation, which may not fully kick in for many years.

This is one reason for the projection of a sub-par economic recovery, more of a U-shape than a V. Waiting for the full benefits of lower tax-rates (and interest rates), entrepreneurs, investors and, yes, rich people, will delay their risk-taking transactions. Perhaps Congress will see a better light this spring and accelerate the whole rate-reduction package. At least future tax-rates are headed down, not up.

But the key point is that declining T-bill rates imply rising capitalized profits. Capitalized earnings are a good guidepost for the S&P 500 stock market index, which could rise to 1,560 by yearend. While that's only slightly above the 1,527 peak registered a year ago, it would be a good leg up on the next bull phase. Keep the faith, investors. Better times are coming.